{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T08:38:23Z","timestamp":1793090303540,"version":"4.5.0"},"reference-count":86,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008349","name":"Boehringer Ingelheim","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008349","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.critrevonc.2026.105619","type":"journal-article","created":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T07:11:16Z","timestamp":1790147476000},"page":"105619","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Innovative therapies for HER2-altered non-small cell lung cancer: A narrative review"],"prefix":"10.1016","volume":"227","author":[{"given":"Oscar","family":"Arrieta","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Caball\u00e9-P\u00e9rez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis","family":"Cabrera-Miranda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andr\u00e9s F.","family":"Cardona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Davila-Dupont","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario","family":"Velasco-C\u00f3rdoba","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Luis Antonio Cancel","family":"Trevi\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"18","key":"10.1016\/j.critrevonc.2026.105619_bib1","doi-asserted-by":"crossref","first-page":"4910","DOI":"10.1158\/1078-0432.CCR-12-0912","article-title":"Prevalence, clinicopathologic associations, and molecular spectrum of ERBB2 (HER2) tyrosine kinase mutations in lung adenocarcinomas","volume":"18","author":"Arcila","year":"2012","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2026.105619_bib2","unstructured":"AstraZeneca (with Daiichi Sankyo), 2024a. A phase Ib multicenter, open-label study to evaluate the safety and tolerability of trastuzumab deruxtecan (T-DXd) and immunotherapy agents with and without chemotherapy agents in first-line treatment of patients with advanced or metastatic non-squamous non-small cell lung cancer (NSCLC) and human epidermal growth factor receptor 2 (HER2) overexpression (OE) (DESTINY-Lung03) (Clinical Trial Registration No. NCT04686305). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04686305."},{"key":"10.1016\/j.critrevonc.2026.105619_bib3","unstructured":"AstraZeneca (with Daiichi Sankyo), 2024b. An open-label, randomized, multicenter, phase 3 study to assess the efficacy and safety of trastuzumab deruxtecan as first-line treatment of unresectable, locally advanced, or metastatic NSCLC harboring HER2 exon 19 or 20 mutations (DESTINY-Lung04) (Clinical Trial Registration No. NCT05048797). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05048797."},{"key":"10.1016\/j.critrevonc.2026.105619_bib4","unstructured":"AstraZeneca (with Daiichi Sankyo), 2024c. An open-label, single-arm, phase 2 study to evaluate the efficacy and safety of trastuzumab deruxtecan (T-DXd) for patients with HER2-mutant metastatic NSCLC who have disease progression on or after at least one-line of treatment (DESTINY-Lung05) (Clinical Trial Registration No. NCT05246514). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT05246514."},{"issue":"10026","key":"10.1016\/j.critrevonc.2026.105619_bib5","doi-asserted-by":"crossref","first-page":"1415","DOI":"10.1016\/S0140-6736(16)00004-0","article-title":"Routine molecular profiling of patients with advanced non-small-cell lung cancer: Results of a 1-year nationwide programme of the French Cooperative Thoracic Intergroup (IFCT)","volume":"387","author":"Barlesi","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2026.105619_bib6","unstructured":"Bayer, 2024. A phase 3 open-label, randomized, active-controlled, multicenter trial to evaluate the efficacy and safety of orally administered BAY 2927088 compared with standard of care as a first-line therapy in patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) with HER2-activating mutations (Clinical Trial Registration No. NCT06452277). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06452277."},{"key":"10.1016\/j.critrevonc.2026.105619_bib7","unstructured":"Boehringer Ingelheim, 2024a. Beamion BCGC-1: A phase Ib dose escalation and phase II dose optimization, randomized, open-label, multicenter trial of oral zongertinib (BI 1810631) in combination with intravenous trastuzumab deruxtecan (T-DXd) or in combination with intravenous trastuzumab emtansine (T-DM1) for treatment of patients with advanced HER2+ metastatic breast cancer (mBC) and metastatic gastric, gastroesophageal junction, or esophageal adenocarcinoma (mGEAC) (Clinical Trial Registration No. NCT06324357). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06324357."},{"key":"10.1016\/j.critrevonc.2026.105619_bib8","unstructured":"Boehringer Ingelheim, 2024b. Beamion LUNG 2: A phase III, open-label, randomized, active-controlled, multi-centre trial evaluating orally administered zongertinib (BI 1810631) compared with standard of care as first-line treatment in patients with unresectable, locally advanced or metastatic non-squamous non-small cell lung cancer harbouring HER2 tyrosine kinase domain mutations (Clinical Trial Registration No. NCT06151574). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06151574."},{"key":"10.1016\/j.critrevonc.2026.105619_bib9","unstructured":"Boehringer Ingelheim, 2024c. Beamion LUNG-1: An open label, phase I dose escalation trial, with dose confirmation and expansion, of zongertinib (BI 1810631) as monotherapy in patients with advanced or metastatic solid tumors with HER2 aberrations (Clinical Trial Registration No. NCT04886804). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT04886804."},{"key":"10.1016\/j.critrevonc.2026.105619_bib10","unstructured":"Boehringer Ingelheim, 2024d. Beamion PANTUMOR-1: A phase II, multicentre, multicohort, open-label trial to evaluate the efficacy and safety of oral zongertinib (BI 1810631) for the treatment of selected HER2-mutated or overexpressed\/amplified solid tumours (Clinical Trial Registration No. NCT06581432). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06581432."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105619_bib11","doi-asserted-by":"crossref","first-page":"S236","DOI":"10.1016\/j.jtho.2021.01.326","article-title":"P01.02 Trastuzumab deruxtecan plus pembrolizumab in advanced\/metastatic breast or non-small cell lung cancer: a phase 1b study","volume":"16","author":"Borghaei","year":"2021","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105619_bib12","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105619_bib13","first-page":"423","article-title":"EGFR and HER2 gene copy number and response to first-line chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)","volume":"2","author":"Cappuzzo","year":"2007","journal-title":"J. Thoracic Oncol. Off. Pub. Int. Assoc. Study Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105619_bib14","unstructured":"Center for Drug Evaluation and Research, 2024a. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for HER2-mutant non-small cell lung cancer. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-her2-mutant-non-small-cell-lung."},{"key":"10.1016\/j.critrevonc.2026.105619_bib15","unstructured":"Center for Drug Evaluation and Research, 2024b. FDA grants accelerated approval to fam-trastuzumab deruxtecan-nxki for unresectable or metastatic HER2-positive solid tumors. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-fam-trastuzumab-deruxtecan-nxki-unresectable-or-metastatic-her2."},{"key":"10.1016\/j.critrevonc.2026.105619_bib16","unstructured":"Center for Drug Evaluation and Research, 2025. FDA grants accelerated approval to zongertinib for non-squamous NSCLC with HER2 TKD activating mutations. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zongertinib-non-squamous-nsclc-her2-tkd-activating-mutations."},{"key":"10.1016\/j.critrevonc.2026.105619_bib17","unstructured":"Center for Drug Evaluation and Research, 2026, February 26. FDA grants accelerated approval to zongertinib for unresectable or metastatic non-squamous non-small cell lung cancer. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-zongertinib-unresectable-or-metastatic-non-squamous-non-small-cell."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105619_bib18","article-title":"695 Efficacy and safety of trastuzumab deruxtecan (T-DXd) with durvalumab in patients with non-small cell lung cancer (HER2 altered NSCLC) who progressed on anti-PD1\/PD-L1 therapy (HUDSON)","volume":"11","author":"Cheema","year":"2023","journal-title":"J. Immunother. Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105619_bib19","doi-asserted-by":"crossref","first-page":"903","DOI":"10.3390\/genes15070903","article-title":"A Comprehensive review of HER2 in cancer biology and therapeutics","volume":"15","author":"Cheng","year":"2024","journal-title":"Genes"},{"issue":"8","key":"10.1016\/j.critrevonc.2026.105619_bib20","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.1016\/j.jtho.2023.03.016","article-title":"Poziotinib in treatment-naive NSCLC harboring HER2 exon 20 mutations: ZENITH20-4, A multicenter, multicohort, open-label, phase 2 trial (cohort 4)","volume":"18","author":"Cornelissen","year":"2023","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105619_bib21","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1186\/s40425-018-0464-1","article-title":"A novel anti-HER2 anthracycline-based antibody-drug conjugate induces adaptive anti-tumor immunity and potentiates PD-1 blockade in breast cancer","volume":"7","author":"D\u2019Amico","year":"2019","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105619_bib22","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.lungcan.2020.07.017","article-title":"Afatinib in patients with advanced non-small cell lung cancer harboring HER2 mutations, previously treated with chemotherapy: a phase II trial","volume":"147","author":"Fan","year":"2020","journal-title":"Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105619_bib23","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.3390\/cancers16112018","article-title":"HER2-Altered Non-Small Cell Lung Cancer: a Journey from Current Approaches to Emerging Strategies","volume":"16","author":"Ferrari","year":"2024","journal-title":"Cancers"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105619_bib24","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1016\/j.jtho.2016.11.398","article-title":"MA04.02 neratinib \u00b1 temsirolimus in HER2-mutant lung cancers: an international, randomized phase II study","volume":"12","author":"Gandhi","year":"2017","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105619_bib25","doi-asserted-by":"crossref","first-page":"S5","DOI":"10.1016\/S1556-0864(25)00198-4","article-title":"3O: phase I\/II SOHO-01 study of BAY 2927088 in patients with previously treated HER2-mutant NSCLC: Safety and efficacy results from 2 expansion cohorts","volume":"20","author":"Girard","year":"2025","journal-title":"J. Thorac. Oncol."},{"issue":"31","key":"10.1016\/j.critrevonc.2026.105619_bib26","doi-asserted-by":"crossref","first-page":"4852","DOI":"10.1200\/JCO.23.01361","article-title":"Trastuzumab deruxtecan in patients with HER2-mutant metastatic non-small-cell lung cancer: primary results from the randomized, phase II DESTINY-Lung02 trial","volume":"41","author":"Goto","year":"2023","journal-title":"J. Clin. Oncol."},{"issue":"2\u20133","key":"10.1016\/j.critrevonc.2026.105619_bib27","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0169-5002(01)00183-0","article-title":"Use of neuroendocrine markers, p53, and HER2 to predict response to chemotherapy in patients with stage III non-small cell lung cancer: a Cancer and Leukemia Group B study","volume":"33","author":"Graziano","year":"2001","journal-title":"Lung Cancer"},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105619_bib28","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s40487-017-0050-6","article-title":"EGFR inhibitors and cutaneous complications: A practical approach to management","volume":"5","author":"Guggina","year":"2017","journal-title":"Oncol. Ther."},{"issue":"6","key":"10.1016\/j.critrevonc.2026.105619_bib29","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1200\/JCO.2017.75.3780","article-title":"Targeted therapy for advanced solid tumors on the basis of molecular profiles: Results from MyPathway, an open-label, phase IIa multiple basket study","volume":"36","author":"Hainsworth","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105619_bib30","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.annonc.2022.12.009","article-title":"Oncogene-addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up","volume":"34","author":"Hendriks","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105619_bib31","doi-asserted-by":"crossref","first-page":"S989","DOI":"10.1016\/j.annonc.2021.08.1864","article-title":"1261P Trastuzumab\/pertuzumab combination therapy in advanced pre-treated HER2-mutated non-small cell lung cancer: Results of a DRUP trial cohort","volume":"32","author":"Henegouwen","year":"2021","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105619_bib32","doi-asserted-by":"crossref","first-page":"e65","DOI":"10.1016\/j.cllc.2022.10.008","article-title":"A Phase I, Open-Label, Dose Confirmation, Escalation, and Expansion Trial of BI 1810631 as Monotherapy in Patients With Advanced or Metastatic Solid Tumors With HER2 Aberrations","volume":"24","author":"Heymach","year":"2023","journal-title":"Clin. Lung Cancer"},{"issue":"11","key":"10.1016\/j.critrevonc.2026.105619_bib33","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1200\/JCO-24-01727","article-title":"HER2-Selective Tyrosine Kinase Inhibitor, Zongertinib (BI 1810631), in Patients With Advanced\/Metastatic Solid Tumors With HER2 Alterations: A Phase Ia Dose-Escalation Study","volume":"43","author":"Heymach","year":"2025","journal-title":"J. Clin. Oncol. Off. J. Am. Soc. Clin. Oncol."},{"issue":"23","key":"10.1016\/j.critrevonc.2026.105619_bib34","doi-asserted-by":"crossref","first-page":"2321","DOI":"10.1056\/NEJMoa2503704","article-title":"Zongertinib in previously treated HER2-mutant non-small-cell lung cancer","volume":"392","author":"Heymach","year":"2025","journal-title":"N. Engl. J. Med."},{"issue":"9","key":"10.1016\/j.critrevonc.2026.105619_bib35","doi-asserted-by":"crossref","first-page":"1449","DOI":"10.1038\/sj.bjc.6600286","article-title":"Evaluation of HER-2\/neu gene amplification and protein expression in non-small cell lung carcinomas","volume":"86","author":"Hirsch","year":"2002","journal-title":"Br. J. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105619_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s41698-024-00720-9","article-title":"Molecular landscape of ERBB2 alterations in 3000 advanced NSCLC patients","volume":"8","author":"Hong","year":"2024","journal-title":"NPJ Precis. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105619_bib37","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.jtho.2017.10.032","article-title":"A phase II study of trastuzumab emtansine in HER2-positive non-small cell lung cancer","volume":"13","author":"Hotta","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"16_","key":"10.1016\/j.critrevonc.2026.105619_bib38","volume":"42","author":"Johnson","year":"2024","journal-title":"J. Clin. Oncol."},{"issue":"522","key":"10.1016\/j.critrevonc.2026.105619_bib39","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aax2693","article-title":"Hair eruption initiates and commensal skin microbiota aggravate adverse events of anti-EGFR therapy","volume":"11","author":"Klufa","year":"2019","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105619_bib40","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1146\/annurev-biochem-060614-034402","article-title":"A structural perspective on the regulation of the epidermal growth factor receptor","volume":"84","author":"Kovacs","year":"2015","journal-title":"Ann. Rev. Biochem."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105619_bib41","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1093\/annonc\/mdv186","article-title":"Targeting HER2 aberrations as actionable drivers in lung cancers: Phase II trial of the pan-HER tyrosine kinase inhibitor dacomitinib in patients with HER2-mutant or amplified tumors","volume":"26","author":"Kris","year":"2015","journal-title":"Ann. Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105619_bib42","first-page":"477","article-title":"Impact of HER2 gene and protein status on the treatment outcome of cisplatin-based chemoradiotherapy for locally advanced non-small cell lung cancer","volume":"3","author":"Kuyama","year":"2008","journal-title":"J. Thoracic Oncol. Off. Pub. Int. Assoc. Study Lung Cancer"},{"issue":"12","key":"10.1016\/j.critrevonc.2026.105619_bib43","doi-asserted-by":"crossref","first-page":"3824","DOI":"10.21037\/tlcr-24-856","article-title":"A potential central nervous system niche for trastuzumab deruxtecan in patients with HER2-expressing non-small cell lung cancer","volume":"13","author":"Lazaratos","year":"2024","journal-title":"Transl. Lung Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105619_bib44","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1200\/JCO.21.01323","article-title":"Poziotinib in non-small-cell lung cancer harboring HER2 exon 20 insertion mutations after prior therapies: ZENITH20-2 Trial","volume":"40","author":"Le","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105619_bib45","doi-asserted-by":"crossref","first-page":"1819","DOI":"10.1056\/NEJMoa2511065","article-title":"Sevabertinib in advanced HER2-mutant non-small-cell lung cancer","volume":"393","author":"Le","year":"2025","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2026.105619_bib46","doi-asserted-by":"crossref","first-page":"S762","DOI":"10.1016\/j.annonc.2023.09.2354","article-title":"1321MO Trastuzumab deruxtecan (T-DXd) in patients (pts) with HER2 (ERBB2)-mutant (HER2m) metastatic non\u2013small cell lung cancer (NSCLC) with and without brain metastases (BMs): Pooled analyses from DESTINY-Lung01 and DESTINY-Lung02","volume":"34","author":"Li","year":"2023","journal-title":"Ann. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105619_bib47","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1016\/j.jtho.2015.10.025","article-title":"HER2 amplification and HER2 mutation are distinct molecular targets in lung cancers","volume":"11","author":"Li","year":"2016","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105619_bib48","doi-asserted-by":"crossref","first-page":"2532","DOI":"10.1200\/JCO.2018.77.9777","article-title":"Ado-trastuzumab emtansine for patients with HER2-mutant lung cancers: Results from a phase II basket trial","volume":"36","author":"Li","year":"2018","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105619_bib49","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab deruxtecan in HER2-mutant non-small-cell lung cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105619_bib50","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/S1470-2045(25)00012-9","article-title":"Trastuzumab rezetecan, a HER2-directed antibody-drug conjugate, in patients with advanced HER2-mutant non-small-cell lung cancer (HORIZON-Lung): Phase 2 results from a multicentre, single-arm study","volume":"26","author":"Li","year":"2025","journal-title":"Lancet Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105619_bib51","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1186\/s12967-025-06589-x","article-title":"Research advancements of antibody drug conjugates in non-small cell lung cancer with HER2 alterations","volume":"23","author":"Liu","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.critrevonc.2026.105619_bib52","doi-asserted-by":"crossref","first-page":"S1189","DOI":"10.1016\/j.annonc.2020.08.2294","article-title":"LBA61 First analysis of RAIN-701: Study of tarloxotinib in patients with non-small cell lung cancer (NSCLC) EGFR exon 20 insertion, HER2-activating mutations & other solid tumours with NRG1\/ERBB gene fusions","volume":"31","author":"Liu","year":"2020","journal-title":"Ann. Oncol."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105619_bib53","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1200\/JCO.21.01455","article-title":"Combination of trastuzumab, pertuzumab, and docetaxel in patients with advanced non-small-cell lung cancer harboring HER2 mutations: Results from the IFCT-1703 R2D2 trial","volume":"40","author":"Mazieres","year":"2022","journal-title":"J. Clin. Oncol."},{"issue":"16","key":"10.1016\/j.critrevonc.2026.105619_bib54","doi-asserted-by":"crossref","first-page":"1997","DOI":"10.1200\/JCO.2012.45.6095","article-title":"Lung cancer that harbors an HER2 mutation: Epidemiologic characteristics and therapeutic perspectives","volume":"31","author":"Mazi\u00e8res","year":"2013","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105619_bib55","unstructured":"National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines\u00ae): Non\u2013Small Cell Lung Cancer. Version 4. 2026. NCCN [Internet]. 2026 Mar 6 [cited 2026 Feb 26]; Available from: https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/nscl.pdf. (n.d.)."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105619_bib56","doi-asserted-by":"crossref","first-page":"S599","DOI":"10.1016\/j.jtho.2018.08.901","article-title":"P1.13-44 Safety, PK, and preliminary antitumor activity of the oral EGFR\/HER2 exon 20 inhibitor TAK-788 in NSCLC","volume":"13","author":"Neal","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105619_bib57","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1016\/j.jtho.2021.11.003","article-title":"The 2021 WHO Classification of Lung Tumors: Impact of advances since 2015","volume":"17","author":"Nicholson","year":"2022","journal-title":"J. Thorac. Oncol."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105619_bib58","doi-asserted-by":"crossref","first-page":"4380","DOI":"10.1002\/cncr.32461","article-title":"Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers","volume":"125","author":"Offin","year":"2019","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.critrevonc.2026.105619_bib59","doi-asserted-by":"crossref","first-page":"5097","DOI":"10.1158\/1078-0432.CCR-15-2822","article-title":"DS-8201a, a novel HER2-targeting ADC with a novel DNA topoisomerase I inhibitor, demonstrates a promising antitumor efficacy with differentiation from T-DM1","volume":"22","author":"Ogitani","year":"2016","journal-title":"Clin. Cancer Res."},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105619_bib60","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1111\/cas.12966","article-title":"Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity","volume":"107","author":"Ogitani","year":"2016","journal-title":"Cancer Sci."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105619_bib61","doi-asserted-by":"crossref","first-page":"S105","DOI":"10.1016\/j.jtho.2024.09.189","article-title":"MA12.10 zongertinib (BI 1810631) for HER2-positive solid tumors with brain metastases: Subanalysis of the Beamion LUNG-1 trial","volume":"19","author":"Opdam","year":"2024","journal-title":"J. Thorac. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105619_bib62","first-page":"n71","article-title":"The PRISMA 2020 statement: An updated guideline for reporting systematic reviews","author":"Page","year":"2021","journal-title":"BMJ (Clin. Res. Ed. ) 372"},{"key":"10.1016\/j.critrevonc.2026.105619_bib63","doi-asserted-by":"crossref","first-page":"S873","DOI":"10.1016\/j.annonc.2024.08.1450","article-title":"1395TiP A randomized phase III trial evaluating oral BAY 2927088, compared with standard of care, as first-line treatment of locally advanced or metastatic NSCLC harboring HER2-activating mutations (SOHO-02)","volume":"35","author":"Passaro","year":"2024","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105619_bib64","doi-asserted-by":"crossref","first-page":"474","DOI":"10.1073\/pnas.0808930106","article-title":"HER2YVMA drives rapid development of adenosquamous lung tumors in mice that are sensitive to BIBW2992 and rapamycin combination therapy","volume":"106","author":"Perera","year":"2009","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.critrevonc.2026.105619_bib65","doi-asserted-by":"crossref","first-page":"S848","DOI":"10.1016\/j.annonc.2023.09.2538","volume":"34","author":"Planchard","year":"2023","journal-title":"Ann. Oncol."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105619_bib66","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1038\/nrc1977","article-title":"Topoisomerase I inhibitors: Camptothecins and beyond","volume":"6","author":"Pommier","year":"2006","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.critrevonc.2026.105619_bib67","doi-asserted-by":"crossref","unstructured":"Popat S., Yamamoto N., Girard N. Zongertinib as first line treatment in patients with advanced HER2 mutant NSCLC: Beamion LUNG 1. Oral presentation at the European Society for Medical Oncology (ESMO) Congress 2025; October 17\u201321, 2025. (n.d.).","DOI":"10.1016\/j.annonc.2025.09.088"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105619_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.esmoop.2022.100395","article-title":"Consensus for HER2 alterations testing in non-small-cell lung cancer","volume":"7","author":"Ren","year":"2022","journal-title":"ESMO Open."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105619_bib69","doi-asserted-by":"crossref","first-page":"e31","DOI":"10.1200\/JCO-25-01061","article-title":"Therapy for stage IV non-small cell lung cancer with driver alterations: ASCO Living Guideline, Version 2025.1","volume":"43","author":"Reuss","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105619_bib70","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ccell.2019.09.001","article-title":"Pan-cancer landscape and analysis of ERBB2 mutations identifies poziotinib as a clinically active inhibitor and enhancer of T-DM1 activity","volume":"36","author":"Robichaux","year":"2019","journal-title":"Cancer Cell."},{"issue":"18","key":"10.1016\/j.critrevonc.2026.105619_bib71","doi-asserted-by":"crossref","first-page":"4705","DOI":"10.3390\/cancers13184705","article-title":"Current landscape of non-small cell lung cancer: Epidemiology, histological classification, targeted therapies, and immunotherapy","volume":"13","author":"Rodak","year":"2021","journal-title":"Cancers"},{"issue":"10, ement","key":"10.1016\/j.critrevonc.2026.105619_bib72","first-page":"S4","article-title":"PL04.04 Primary phase Ib analysis of Beamion LUNG-1: zongertinib (BI 1810631) in patients with HER2 mutation-positive NSCLC","volume":"19","author":"Ruiter","year":"2024","journal-title":"Lung Cancer"},{"key":"10.1016\/j.critrevonc.2026.105619_bib73","doi-asserted-by":"crossref","first-page":"S9","DOI":"10.1016\/S0959-8049(22)00827-9","article-title":"BAY 2927088: The first non-covalent, potent, and selective tyrosine kinase inhibitor targeting EGFR exon 20 insertions and C797S resistance mutations in NSCLC","volume":"174","author":"Siegel","year":"2022","journal-title":"Eur. J. Cancer"},{"issue":"4","key":"10.1016\/j.critrevonc.2026.105619_bib74","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1016\/S1470-2045(24)00064-0","article-title":"Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): Primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial","volume":"25","author":"Smit","year":"2024","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105619_bib75","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1158\/2159-8290.CD-19-1014","article-title":"Targeting HER2 with trastuzumab deruxtecan: A dose-expansion, phase I study in multiple advanced solid tumors","volume":"10","author":"Tsurutani","year":"2020","journal-title":"Cancer Discov."},{"issue":"10","key":"10.1016\/j.critrevonc.2026.105619_bib76","doi-asserted-by":"crossref","first-page":"S324","DOI":"10.1016\/j.jtho.2018.08.244","article-title":"OA02.07 Updated results of phase 1 study of DS-8201a in HER2-expressing or \u2013mutated advanced non-small-cell lung cancer","volume":"13","author":"Tsurutani","year":"2018","journal-title":"J. Thorac. Oncol."},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105619_bib77","doi-asserted-by":"crossref","first-page":"326","DOI":"10.1186\/s12885-018-4277-x","article-title":"Outcomes of pemetrexed-based chemotherapies in HER2-mutant lung cancers","volume":"18","author":"Wang","year":"2018","journal-title":"BMC Cancer"},{"issue":"7","key":"10.1016\/j.critrevonc.2026.105619_bib78","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1038\/s43018-022-00412-y","article-title":"Discovery of potent and selective HER2 inhibitors with efficacy against HER2 exon 20 insertion-driven tumors, which preserve wild-type EGFR signaling","volume":"3","author":"Wilding","year":"2022","journal-title":"Nat. Cancer"},{"issue":"1","key":"10.1016\/j.critrevonc.2026.105619_bib79","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1158\/2159-8290.CD-24-0306","article-title":"Zongertinib (BI 1810631), an irreversible HER2 TKI, spares EGFR signaling and improves therapeutic response in preclinical models and patients with HER2-driven cancers","volume":"15","author":"Wilding","year":"2025","journal-title":"Cancer Discov."},{"issue":"_4","key":"10.1016\/j.critrevonc.2026.105619_bib80","first-page":"S1625","article-title":"LBA5\u2014Zongertinib in patients with HER2-mutant NSCLC: Updated analysis of beamion LUNG-1","volume":"35","author":"Yamamoto","year":"2024","journal-title":"Ann. Oncol."},{"issue":"2","key":"10.1016\/j.critrevonc.2026.105619_bib81","doi-asserted-by":"crossref","first-page":"753","DOI":"10.21037\/tlcr-20-559","article-title":"Exon 20 YVMA insertion is associated with high incidence of brain metastasis and inferior outcome of chemotherapy in advanced non-small cell lung cancer patients with HER2 kinase domain mutations","volume":"10","author":"Yang","year":"2021","journal-title":"Transl. Lung Cancer Res."},{"issue":"29","key":"10.1016\/j.critrevonc.2026.105619_bib82","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1200\/JCO.23.02044","article-title":"Safety, efficacy, and pharmacokinetics of SHR-A1811, a human epidermal growth factor receptor 2-directed antibody-drug conjugate, in human epidermal growth factor receptor 2-expressing or mutated advanced solid tumors: A global phase I trial","volume":"42","author":"Yao","year":"2024","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2026.105619_bib83","unstructured":"Yonsei University, 2024. A phase 2 trial to assess efficacy and safety of T-DXd in HER2-mutant advanced lung cancer patients with asymptomatic brain metastases. (Clinical Trial Registration No. NCT06250777). clinicaltrials.gov. https:\/\/clinicaltrials.gov\/study\/NCT06250777."},{"issue":"3","key":"10.1016\/j.critrevonc.2026.105619_bib84","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.lungcan.2014.06.007","article-title":"HER2 status in lung adenocarcinoma: A comparison of immunohistochemistry, fluorescence in situ hybridization (FISH), dual-ISH, and gene mutations","volume":"85","author":"Yoshizawa","year":"2014","journal-title":"Lung Cancer (Amsterdam Netherlands)"},{"issue":"5","key":"10.1016\/j.critrevonc.2026.105619_bib85","doi-asserted-by":"crossref","DOI":"10.1136\/bcr-2022-253260","article-title":"Metastatic HER2-amplified non-small-cell lung cancer treated with trastuzumab deruxtecan","volume":"16","author":"Yun","year":"2023","journal-title":"BMJ Case Rep."},{"issue":"24","key":"10.1016\/j.critrevonc.2026.105619_bib86","doi-asserted-by":"crossref","first-page":"2753","DOI":"10.1200\/JCO.20.00297","article-title":"Pyrotinib in HER2-mutant advanced lung adenocarcinoma after platinum-based chemotherapy: A multicenter, open-label, single-arm, phase II study","volume":"38","author":"Zhou","year":"2020","journal-title":"J. Clin. Oncol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005068?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842826005068?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,27]],"date-time":"2026-10-27T07:55:32Z","timestamp":1793087732000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842826005068"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":86,"alternative-id":["S1040842826005068"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105619","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Innovative therapies for HER2-altered non-small cell lung cancer: A narrative review","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2026.105619","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105619"}}